Knuff & Co LLC Buys 149 Shares of Danaher Co. (NYSE:DHR)

Knuff & Co LLC raised its stake in Danaher Co. (NYSE:DHR) by 1.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,407 shares of the conglomerate’s stock after acquiring an additional 149 shares during the period. Knuff & Co LLC’s holdings in Danaher were worth $1,930,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of DHR. Heck Capital Advisors LLC bought a new stake in Danaher in the 4th quarter valued at $27,000. Decker Retirement Planning Inc. bought a new stake in Danaher in the 4th quarter valued at $31,000. Golden State Wealth Management LLC bought a new stake in Danaher in the 4th quarter valued at $31,000. Strategic Financial Concepts LLC bought a new stake in Danaher in the 4th quarter valued at $31,000. Finally, Pineridge Advisors LLC grew its stake in shares of Danaher by 63.3% in the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock worth $34,000 after buying an additional 57 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 11.10% of the stock is owned by corporate insiders.

Danaher Trading Up 0.4 %

NYSE DHR opened at $206.01 on Wednesday. The firm has a 50 day simple moving average of $221.55 and a 200-day simple moving average of $241.74. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. Danaher Co. has a one year low of $196.80 and a one year high of $281.70. The firm has a market cap of $147.24 billion, a price-to-earnings ratio of 39.02, a PEG ratio of 2.66 and a beta of 0.82.

Danaher (NYSE:DHR) last issued its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the previous year, the business earned $2.09 EPS. Equities research analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.32 per share. The ex-dividend date is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a yield of 0.62%. This is a boost from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio (DPR) is presently 24.24%.

Analyst Ratings Changes

DHR has been the subject of a number of recent research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $277.00 price objective (down from $299.00) on shares of Danaher in a research note on Thursday, January 30th. Guggenheim initiated coverage on shares of Danaher in a research note on Thursday, December 19th. They issued a “buy” rating and a $275.00 price objective for the company. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research note on Friday, December 13th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Finally, Wells Fargo & Company dropped their price target on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.